本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
Live Webinar Featuring AWS Guest Speakers Speakers: Dipak Thekke, Business Development Lead, Modernization, AWS India & Sriwantha Attanayake, Principal Partner Solution Architect, AWS Australia June 28, 2023, 3:30 PM AEST | 11:00 AM IST JACKSONVILLE, Fla., June 26, 2023 /PRNewswire/ -- SourceFuse, a leading provider of cloud-native, bespoke solutions and services for enterprises, is excited to announce its upcoming webinar, 'Modernize. Optimize. Monetize: Windows Workloads on AWS' on June 28, 2023. Featuring two distinguished AWS guest speakers, this webinar is a must-attend event for business leaders, CXOs, and IT decision makers seeking to harness the power of cloud technologies to drive their organizations forward. REGISTER HERE WHAT: In today's fast-paced business landscape, staying ahead of the competition requires modernization, optimization, and monetization strategies. This webinar brings together AWS and SourceFuse experts to provide invaluable insights on leveraging cloud technologies to propel business growth and innovation, addressing a range of topics including: Modernizing, Optimizing, and Monetizing Legacy Windows Systems: Explore proven strategies to drive business growth by up to 40%* and innovation by modernizing and optimizing legacy Windows systems, while unlocking new monetization opportunities. Running Windows Workloads on AWS: Discover why AWS is exceptionally well-suited for running Windows workloads, providing scalability & flexibility, while reducing Total Cost of Ownership by up to 35%*. Breaking Free from Hardware Refreshes and Licensing Limitations: Learn how to overcome the challenges posed by hardware refresh cycles and long-term licensing agreements, enabling your organization to scale without constraints. Robust Security and Compliance in Transition: Gain insights into maintaining robust security and compliance throughout the transition process, ensuring data protection and meeting regulatory requirements. *SourceFuse was able to achieve these improvements for its customers with support of AWS. Potential results can vary slightly based on the actual use case. The webinar will also cover other crucial topics, including considerations for Windows Server 2012 end-of-support (EOS), the pathway for refactoring Windows applications from .NET Framework to .NET Core/.NET 6+ on AWS, and how AWS compares to Azure in terms of benefits and advantages. ACCESS: Don't miss out on this opportunity to hear about SourceFuse experiences and learn from AWS experts to gain a competitive edge in the market. REGISTER HERE About SourceFuse Media Contact: Vaidant Singh, CMO, SourceFuse, Phone: +1-800-578-3873, vaidant.singh@sourcefuse.com
KUALA LUMPUR, Malaysia, June 26, 2023 (GLOBE NEWSWIRE) -- VCI Global Limited (NASDAQ: VCIG) (“VCI Global”, or the “Company”) announced that it has proposed to acquire a 51% stake in Cogia GmbH from Cogia AG for a purchase consideration of USD5 million. The purchase consideration will be settled by way of issuance of new VCI Global ordinary shares to Cogia AG. Cogia GmbH is wholly owned by Cogia AG, a company listed on Dusseldorf Stock Exchange. Incorporated in Frankfurt am Main, Germany, Cogia GmbH itself is a software company which offers artificial intelligence (“AI”) based, fully privacy-compliant solutions in the areas of secure communications, cybersecurity, Big Data Analytics and web monitoring. Its vast customer portfolio includes major companies from various industries, such as Volkswagen, BMW, Lufthansa, IPSOS and the government of an European Union state. “We at VCI Global feels that AI is the way of the future. This proposed acquisition will further entrench VCI Global’s footprint on global AI related industries and services with the offering of unprecedented AI-enhanced technologies and consultancy services. We also considered Cogia as an ideal partner given the exceptional business opportunities and synergies, fuelled by our common visions. The strong positive feedbacks from capital markets merely endorse our decision to expedite this partnership now through a merger. This merger represents a pivotal moment, propelling us to greater heights,” said Dato’ Victor Hoo, Group Executive Chairman and Chief Executive Officer of VCI Global. "Excited to amplify our partnership with VCI Global through this strategic 51% acquisition, harnessing their financial expertise and core customer connections to fuel our global growth, with a sharp focus on dominating the Asian market," said Pascal Lauria, Founder and Chief Executive Officer of Cogia GmbH. About VCI Global Limited VCI Global is a multi-disciplinary consulting group with key advisory practices in the areas of business and technology. The Company provides business and boardroom strategy services, investor relation services, and technology consultancy services. Its clients range from small-medium enterprises and government-linked agencies to publicly traded companies across a broad array of industries. VCI Global operates solely in Malaysia, with clients predominantly from Malaysia, but also serves some clients from China, Singapore, and the US. For more information on the Company, please log on to https://v-capital.co/. About Cogia GmbH Cogia GmbH is a software company based in Frankfurt am Main, Germany, founded in 2010. The company offers AI-based, fully privacy-compliant solutions in the areas of secure communications, cybersecurity, Big Data Analytics and web monitoring. The customer portfolio includes major companies from many industries, including Volkswagen, BMW, IPSOS, Lufthansa and the government of an EU state. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including without limitation, the Company's ability to achieve profitable operations, customer acceptance of new products, the effects of the spread of Coronavirus (COVID-19) and future measures taken by authorities in the countries wherein the Company has supply chain partners, the demand for the Company's products and the Company's customers' economic condition, the impact of competitive products and pricing, successfully managing and, general economic conditions and other risk factors detailed in the Company's filings with the United States Securities and Exchange Commission. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update the forward-looking statements in this release, except in accordance with applicable law. CONTACT INFORMATION: Issued by Imej Jiwa Communications Sdn Bhd on behalf of VCI Global Limited For media queries, please contact: Imej Jiwa Communications Sdn Bhd Chris Chuah Email: chris@imejjiwa.com
First placebo-controlled randomized trial in HS to report positive topline results using HiSCR75 as the primary endpoint Primary endpoint HiSCR75 met with 29 percentage points (ppt) delta vs placebo (p=0.0002) at week 12, setting a new bar in HS HiSCR50 met with 38 ppt delta vs placebo (p<0.0001), greater delta than observed for any other molecules Other secondary endpoints also reached statistical significance with clinically meaningful improvements at week 12, including HiSCR90, IHS4 and various patient reported outcomes Safety results of sonelokimab consistent with previously reported studies with no new observed safety signals These topline data will be discussed on Monday 26th June, at 2pm CEST/8am EDT, via webcast (registration link below) ZUG, Switzerland, June 25, 2023 – MoonLake Immunotherapeutics (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced positive top-line results from its global Phase 2 MIRA trial evaluating the efficacy and safety of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS). The MIRA trial (M1095-HS-201), which recruited 234 patients, is the first randomized, double-blind, placebo-controlled trial to use Hidradenitis Suppurativa Clinical Response (HiSCR) 75 as its primary endpoint, a higher measure of clinical response versus the HiSCR50 measure used in other clinical trials, therefore representing a landmark milestone in HS clinical development. The trial met its primary endpoint with a significantly greater proportion of patients treated with both sonelokimab 120mg and 240mg achieving HiSCR75 compared to those on placebo at week 12. The primary analysis was based on the most stringent type of analysis for such trials, intent-to-treat non-responder imputation (ITT-NRI). Both doses performed similarly, with the 120mg dose providing the highest delta on HiSCR75 and HiSCR50. The 120mg dose achieved a 29 ppt delta to placebo on HiSCR75 (p=0.0002) and a 38ppt delta to placebo on HiSCR50 (p<0.0001). The results suggest that, as early as week 12, the Nanobody® sonelokimab, relative to placebo, reaches the highest clinical activity among all other therapies tested in similarly stringent pivotal-like trials. In addition, other clinically relevant secondary endpoints, such as HiSCR90, improvements in International Hidradenitis Suppurativa Severity Score System (IHS) 4, abscess/nodule and draining tunnel counts as well as patient reported pain and quality of life outcomes also reached statistical significance at week 12. The high performance of the Nanobody® at 120mg, the dose found to be optimal in psoriasis, demonstrates the advantage of using a smaller biologic with albumin-binding capacity to inhibit IL-17A and IL-17F for the treatment of inflammatory diseases. The safety profile of sonelokimab was consistent with previously reported studies with no new safety signals observed. Overall, sonelokimab continues to show a favorable safety profile, in line with the known profile of IL-17 inhibitors. Jorge Santos da Silva, PhD, Founder and Chief Executive Officer at MoonLake, said: “As part of our efforts to elevate outcomes for patients, we set an ambitious goal for our Nanobody® sonelokimab to ‘meet or beat’ the best results shown in pivotal-like trials of competitors. We have achieved our ‘beat’ goal with the positive outcome of the Phase 2 MIRA trial. In doing so, we have raised the bar for what can be accomplished for HS and these positive topline data provide us with even greater confidence as we look forward to our next steps and our aspiration to become a leader in the inflammation and immunology space.” Kristian Reich, MD, PhD, Founder and Chief Scientific Officer at MoonLake, commented: “The positive topline results from the MIRA trial establish a new era in the treatment of chronic inflammatory diseases, as our Nanobody® sonelokimab indicates a new bar versus what was achieved previously with monoclonal antibodies. Importantly, the results confirm the advantage of the Nanobody’s smaller size versus traditional antibodies in the treatment of diseases in which high-level improvements depend on optimal tissue penetration such as hidradenitis suppurativa and likely psoriatic arthritis. The data also validate sonelokimab’s unique mode of action to efficiently inhibit IL-17F in addition to IL-17A. The positive outcome of the MIRA trial would not have been possible without the support and participation of the patients and investigators to whom we are grateful.” Alexa B. Kimball, MD, MPH, lead investigator of the MIRA trial, investigator at Beth Israel Deaconess Medical Center, Massachusetts, US, and Professor of Dermatology at Harvard Medical School, added: “Hidradenitis suppurativa is a chronic, inflammatory, recurrent, and debilitating skin disease that has profound and wide-ranging impacts across many aspects of patient’s lives. As a physician, I see tremendous need for new treatment options for people living with HS, particularly for treatments to reach high thresholds of response in clinical trials (e.g., HiSCR75 and beyond). The positive high clinical responses observed with sonelokimab in the Phase 2 MIRA trial are encouraging, demonstrating its promise as a potential future treatment option.” These topline data will be discussed on Monday June 26, 2023 at 2pm CEST/8am EDT before the Nasdaq market opens, via webcast at: https://onlinexperiences.com/Launch/QReg/ShowUUID=AF1A77F1-F560-4D58-AE3B-00698698C741&LangLocaleID=1033&GroupID=Onyx A replay of the webcast and the presentation document will be made available at https://ir.moonlaketx.com. The MIRA trial proceeds to week 24, with a 4-week safety follow-up. Important data is being collected regarding longer-term efficacy and safety of sonelokimab, as well as results from switching to sonelokimab from the placebo and the adalimumab arms. Full results from the MIRA trial will be submitted for publication in a peer-reviewed medical journal and for presentation at an upcoming scientific meeting. Sonelokimab has already been successfully assessed in a randomized, placebo-controlled, Phase 2b trial (NCT03384745) in 313 patients with moderate-to-severe plaque-type psoriasis in which it demonstrated a rapid and durable skin clearance (PASI100) with no unexpected safety findings. Sonelokimab is currently being evaluated in a Phase 2 trial (NCT05640245), ‘ARGO’, in patients with active psoriatic arthritis with the primary end-point readout expected in Q4 this year. Sonelokimab is not yet approved for use in any indication. - Ends - About the MIRA trial The MIRA trial (M1095-HS-201) is a global, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of the Nanobody® sonelokimab, administered subcutaneously, in the treatment of adult patients with active moderate-to-severe hidradenitis suppurativa. The trial recruited 234 patients, with the aim to evaluate two different doses of sonelokimab (120mg and 240mg) with placebo control and adalimumab as an active reference arm. The primary endpoint of the trial is the percentage of participants achieving Hidradenitis Suppurativa Clinical Response 75 (HiSCR75), defined as a ≥75% reduction in total abscess and inflammatory nodule (AN) count with no increase in abscess or draining tunnel count relative to baseline. The trial also evaluated a number of secondary endpoints, including the proportion of patients achieving HiSCR50, the change from baseline in International Hidradenitis Suppurativa Severity Score System (IHS4), the proportion of patients achieving a Dermatology Life Quality Index (DLQI) total score of ≤5, and the proportion of patients achieving at least 30% reduction from baseline in Numerical Rating Scale (NRS30) in the Patient’s Global Assessment of Skin Pain (PGA Skin Pain). Further details are available at: https://www.clinicaltrials.gov/ct2/show/NCT05322473 . About MoonLake Immunotherapeutics MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company unlocking the potential of sonelokimab, a novel investigational Nanobody® for the treatment of inflammatory disease, to revolutionize outcomes for patients. Sonelokimab inhibits IL-17A and IL-17F by inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers that drive inflammation. The company’s focus is on inflammatory diseases with a major unmet need, including hidradenitis suppurativa and psoriatic arthritis – conditions affecting millions of people worldwide with a large need for improved treatment options. MoonLake was founded in 2021 and is headquartered in Zug, Switzerland. Further information is available at www.moonlaketx.com. About Nanobodies® Nanobodies® represent a new generation of antibody-derived targeted therapies. They consist of one or more domains based on the small antigen-binding variable regions of heavy-chain-only antibodies (VHH). Nanobodies® have a number of potential advantages over traditional antibodies, including their small size, enhanced tissue penetration, resistance to temperature changes, ease of manufacturing, and their ability to be designed into multivalent therapeutic molecules with bespoke target combinations. The terms Nanobody® and Nanobodies® are trademarks of Ablynx, a Sanofi company. About Sonelokimab Sonelokimab (M1095) is an investigational ~40 kDa humanized Nanobody® consisting of three VHH domains covalently linked by flexible glycine-serine spacers. With two domains, sonelokimab selectively binds with high affinity to IL-17A and IL-17F, thereby inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers. A third central domain binds to human albumin, facilitating further enrichment of sonelokimab at sites of inflammatory edema. Sonelokimab has been assessed in a randomized, placebo-controlled Phase 2b study in 313 patients with moderate-to-severe plaque-type psoriasis. Sonelokimab demonstrated a rapid and durable clinical response (Investigator’s Global Assessment Score 0 or 1, Psoriasis Area and Severity Index 90/100) in patients with moderate-to-severe plaque-type psoriasis. Sonelokimab was generally well tolerated, with a safety profile similar to the active control, secukinumab (Papp KA, et al. Lancet. 2021; 397:1564-1575). In an earlier Phase 1 study in patients with moderate-to-severe plaque-type psoriasis, sonelokimab has been shown to decrease (to normal skin levels) the cutaneous gene expression of pro-inflammatory cytokines and chemokines (Svecova D. J Am Acad Dermatol. 2019;81:196–203). Currently, a global phase 2 trial in psoriatic arthritis (NCT05640245, M1095-PSA-201, “ARGO”) including multiple arms and over 200 patients is ongoing (announced on Dec 14, 2022). About Hidradenitis Suppurativa Hidradenitis suppurativa is a severely debilitating chronic skin condition resulting in irreversible tissue destruction. HS manifests as painful inflammatory skin lesions, typically around the armpits, groin, and buttocks. Over time, uncontrolled and inadequately treated inflammation can result in irreversible tissue destruction and scarring. The disease affects 0.05–4.1% of the global population, with three times more females affected than males. Onset typically occurs in early adulthood and HS has a profound negative impact on quality of life, with a higher morbidity than other dermatologic conditions. There is increasing scientific evidence to support IL-17A- and IL-17F-mediated inflammation as a key driver of the pathogenesis of HS, with other identified risk factors including genetics, cigarette smoking, and obesity. Cautionary Statement Regarding Forward Looking Statements This press release contains certain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding MoonLake’s expectations, hopes, beliefs, intentions or strategies regarding the future including, without limitation, statements regarding: plans for clinical trials and research and development programs; and the anticipated timing of the results from those trials, including completing the MIRA trial; and the efficacy of our products, if approved, including in relation to other products. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that such statement is not forward looking. Forward-looking statements are based on current expectations and assumptions that, while considered reasonable by MoonLake and its management, as the case may be, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with MoonLake’s business in general and limited operating history, difficulty enrolling patients in clinical trials, and reliance on third parties to conduct and support its clinical trials, and the other risks described in or incorporated by reference into MoonLake’s Annual Report on Form 10-K for the year ended December 31, 2022 and subsequent filings with the Securities and Exchange Commission. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. MoonLake does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or in the events, conditions or circumstances on which any such statement is based. MoonLake Immunotherapeutics Investors Matthias Bodenstedt, CFO info@moonlaketx.com MoonLake Immunotherapeutics Media Patricia Sousa media@moonlaketx.com Consilium Strategic Communications Mary-Jane Elliott, Namrata Taak, Genevieve Wilson Tel: +44 (0) 20 3709 5700 media@moonlaketx.com MoonLake@consilium-comms.com
Regal Holding.CO, Taiwan's first listed jewelry company (Regal Holding-KY, 4807), led by Ms. Lin Ru-yin, General Manager, who has over 30 years of experience in positioning Thai Day's jewelry in the European and American markets. In 2020, through its Taiwan subsidiary "Regal Holding," it established the platform "D.Vita Design Dream" with the concept of nurturing designers. With the three core principles of "Love and Sharing," "Cross-disciplinary Collaboration," and "Joint Creation," D.Vita aims to gather the power of 0.01 and achieve extraordinary visions. "D.Vita Design Dream" aims to enter the market through "Star Search" and "Star Building," expanding its presence in the international market through cross-border digital marketing. It also launched the online fashion shopping platform "ReModa Design Nest." In its second year, the shining star selection of D.Vita, Regal Holding (RIC), has signed a strategic partnership agreement with DE Global Agency. This partnership not only provides international business opportunities for jewelry designers in Taiwan but also offers guidance in jewelry exhibitions and overseas award applications. The winner of the first D.Vita Design Shining Star was the designer brand "One N Only" by Wu Xiaoping. The General Manager presented a round-trip business class ticket to Thailand and short-term incubation training at Thai Day's jewelry factory. Due to Wu Xiaoping's confirmed COVID-19 case, her sister attended the award ceremony on her behalf. The other finalists were designers Zhou Wanying and Peng Liting. Ku Chi-chun, the founder of DE Global Agency, encouraged aspiring designers on the challenging path of realizing their dreams. He believed that whether it is pure art or jewelry design, it requires great passion and a relentless pursuit of dreams. As an artist himself, Ku Chi-chun deeply understood the hardships and challenges faced by art creators in their journey from creation to the market, from individual to teamwork, which requires time and honing of skills. DE Global Agency provides comprehensive overseas art consulting services, private auction services, and one-on-one overseas art consulting for the career needs of art creators and designers. By utilizing the channels and tools of Butterfly Art Product Power, including virtual and physical solutions, product analysis models, brand planning, and subscription-based community editors, DE Global Agency supports the growing demand and commercialization of art and design in Taiwan. The collaboration between the designers of D.Vita Design Dream and art exhibitions enters the upgraded "Art Design Collaboration Program 2.0," which strengthens the systematic and comprehensive incubation program, addressing the lack of market concepts among art and design professionals and expanding Taiwan's art and design landscape. Regal Holding.CO achieved a revenue of nearly 2.1 billion NTD in 2021 and is an OEM factory for several internationally renowned brands in Europe and the United States. The selected emerging designers of "D.Vita Design Dream" have completed their school learning phase and are currently moving towards employment, entrepreneurship, or the international design stage. The selection process involves three designated theme design concepts, and the chosen D.Vita featured designers enter the "Accelerated Incubation" phase. They receive practical guidance from design concepts and 3D modeling to product sampling and new product launches. Finally, the annual D.Vita Shining Star is selected. Day's Group is also willing to provide opportunities for international brand creative design internships and development, giving Taiwanese art and design creators the chance to broaden their horizons and expand their international perspectives.
MUNICH, June 25, 2023 /PRNewswire/ -- On June 14-16, the European Smart Energy Expo hosted by the German Solar Industry Alliance was grandly opened in Munich, Germany. The world's top energy storage company, EVE, presented its big LFP cell "Mr big"-LF560K at the exhibition and signed a strategic cooperation of 23GWh on the booth. During the exhibition, EVE showcased comprehensive solutions for international customers, such as utility ESS, Telecom ESS, household ESS, Marine power, etc. At the same time, we held the "Next Generation ESS Cell for TWh -LF560K" themed new product launch, leading the new wave of energy TWh era. It is reported that LF560K redefines ESS with the three advantages of "Easier, Safer and Super Economic", which can effectively meet the trend of TWh era and solve the problems of management complexity, thermal runaway and economy in the era of large-scale power plants. With years of practical application and good market feedback, EVE's booth attracted many customers to communicate with us. Among them, the United States head energy storage integration enterprise Powin and American Battery Solutions (ABS) held a signing ceremony with EVE, reaching a total of 23GWh of strategic cooperation. In this collaboration, EVE will provide part of the production capacity for Powin's flagship 1850MWh Waratah superbattery to enhance its safety and performance. With the advent of the TWh era, Powin and EVE are also about to work together to build the first single energy storage system super GWh project. In cooperation with ABS, EVE LF280K cells will be used in ABS' new battery storage system, TeraStor™. The system is compatible with at least 160 different operating conditions at different multipliers and temperatures, requiring the highest standards and performance of the cells. With the support of EVE products, TeraStor™ has passed the reliability analysis test by Reliant Labs and completed UL9540A test, making it one of the most reliable energy storage systems on the market today. Up to now, EVE has completed the layout of multi-form and multi-technology energy storage products, with full product solutions from cell, BMS, module to system, covering four major application fields: utility, telecommunication, household and marine. For different segments of the market, we provide the best adaptable solutions for different requirements such as product life, multiplier, safety, temperature control and cost. In view of its excellent product strength and ultimate manufacturing capability, EVE has reached cooperation with BMW, Daimler, Hyundai, Jaguar Land Rover and other international car companies, and its overseas business expansion is gaining momentum. Recently, EVE has announced the construction of factories in Malaysia and Hungary, continuing to increase its overseas layout. The appearance of EVE at THE SMARTER E EUROPE 2023 demonstrates its super strength of global layout and global delivery. In the future, EVE will continue to lead the direction of energy storage innovation, provide more cost-effective, more efficient and more stable energy storage solutions, to help sustainable development and build a green and low-carbon future.
CHANGSHA, China, June 25, 2023 /PRNewswire/ -- Recently, Niccolo Changsha once again joined hands with contemporary artist Mr Fang Shibiao. Inspired by Mr Fang's "SHE" art series exhibition created from a female perspective, Niccolo Changsha presented a wonderfully interpreted wedding art salon, integrating art, romance and modernity, while jointly exploring the romantic nature of the beloved. The salon was created in collaboration with a total of eight high-end wedding purveyors, including Changsha IFS and Modern Radio Broadcasting, Dream Maker Wedding, Muen Wedding, Timeless Videography, Jinxi Photography, Surprise holiday, Han's Selection of Jewelry, and Xibei Wedding Gift, as well as Changsha Ba Yi Motorcade. The entire event was carefully executed in three chapters: guided art tour, a wedding fashion show and an interactive artistic session. Together with the artfully crafted desserts by the hotel's French chef Mr Ménad Berkani and his team, the media and guests enjoyed a triple feast of sights, taste and touch. Niccolo Changsha Wedding Salon The event officially opened at 2:30 pm. Our team led the guests to admire the 11 works of the Fang Shibiao Art Exhibition, explaining the creative inspiration and concept of each piece, and experiencing the freedom and blossoming attitude of women at each stage of life. At the end of the exhibition, music played, and the welcome lobby on the hotel's 4th floor evolved into a fashion show. Professional male and female models appeared in elegant wedding outfits and moved gracefully to the rhythm of the music, changing through different postures to interpret the beautiful wedding gowns, and pushing the atmosphere to a climax. Afterwards, the guests were invited to move to The Conservatory on the 8th floor and began to freely create art, showing great interest and enthusiasm in their eagerness to pick up the brushes and improvise paint on canvas. This year, Niccolo Changsha continues to integrate the concept of art into weddings to increase guests' understanding, awareness and unique experiences of the hotel venue and services, all while bringing prospective newlyweds together. As the landmark hotel in the Star City, Niccolo Changsha continues to be a beacon of fashion and elegance, focuses on creativity and artistic presentation, continuously infuses new concepts into the market, serves as a leader for the fashionable and exquisite lifestyle of the Star City, bringing everyone together to experience more beauty in life. Special wedding offers are ongoing. For more information and reservations, please call 0731-88958888. About Niccolo Changsha New Encounters. Timeless Pleasures. Niccolo Changsha is located in Hunan capital's premier address in Furong District entertainment and business hub. Open in October 2018, the hotel offers 241 contemporary urban chic rooms and spectacular suites between the 86th and 92nd floors of Changsha IFS Tower One. Situated in the most vibrant part of the city, the hotel's facilities include contemporary function and meeting spaces offering scenic views of the city and Xiang river, elaborate conference and social event venues including The Conservatory, the luxurious Niccolo Ballroom, a sophisticated Tea Lounge, Bar 93, Niccolo Kitchen, The Spa at Niccolo and Fitness Centre. Reservations may be made at niccolohotels.com. About DISCOVERY Loyalty A memorable trip demands more than a comfortable stay. DISCOVERY, an award-winning global loyalty program, provides 11 million members recognition and perks across over 570 hotels, resorts and palaces in 85 countries. Elite members have the opportunity to immerse themselves in local culture through Local Experiences andwee distinctive activities that capture an authentic taste of each destination. For more information, visit discoveryloyalty.com
A12 藝術空間
business
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
